Salesforce
CRM
Coinbase
COIN
Oracle
ORCL
4
Microsoft
MSFT
5
Vale SA
VALE
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 2.176
- -0.074-3.29%
Trading Apr 24 11:51 ET
219.14MMarket Cap-0.87P/E (TTM)
2.276High2.160Low75.95KVolume2.250Open2.250Pre Close167.90KTurnover0.11%Turnover RatioLossP/E (Static)100.71MShares7.25052wk High0.48P/B157.96MFloat Cap1.84552wk Low--Dividend TTM72.59MShs Float29.880Historical High--Div YieldTTM5.16%Amplitude1.845Historical Low2.210Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Acelyrin Stock Forum
$737 Million Deal Reshapes Immunology Sector: Inside Alumis and ACELYRIN's Strategic Merger Revolution
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Friday, 4th April at 4:34 pm
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet
Boards unanimously recommend stockholders vote "FOR" the merger
Transaction expected to be completed in second quarter of 2025
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceuti...
WSJ· 4 mins ago
Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable...
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
share buyback at $3, shorts only touched this a tiny bit. I think shorts would only touch this once it got over $3.
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
$Acelyrin (SLRN.US)$
has options
nfa
$Acelyrin (SLRN.US)$
has options
nfa
No comment yet